EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische Studie

Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT

Huaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang, Jun Yao iD, Shuang Leng, Xiumin Li, Li Lin, Jinping Chen, Songnan Zhang, Xia Qin, Zhiquan Qin, Tienan Yi und 26 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-01308 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Huaqiang Zhou und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical …. Hauptthemen laut MEDLINE: Antiemetics, Antineoplastic Agents, Cisplatin, Nausea. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Mixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors. This study was designed to evaluate the efficacy and safety of HR20013 plus dexamethasone (DEX) versus fosaprepitant (FAPR) plus PALO + DEX for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). METHODS This is a noninferiority study. Chemotherapy-naïve patients were randomly assigned 1:1 to receive HR20013 (day 1) or FAPR + PALO (day 1) before each cycle of cisplatin-based HEC (two cycles in total), together with oral DEX (day 1-4). The primary end point was overall (0-120 hours) complete response (CR; no vomiting/no rescue therapy) rate in cycle 1. The key secondary end point was CR rate at the beyond delayed phase (120-168 hours) in cycle 1. RESULTS Three hundred seventy-three patients were enrolled to receive HR20013 + DEX and 377 to FAPR + PALO + DEX. The overall CR rate in cycle 1 was 77.7% for HR20013 + DEX and 78.2% for FAPR + PALO + DEX (difference = –0.9% [95% CI, –6.7 to 5.0]; one-sided P < .01), demonstrating that HR20013 + DEX was noninferior to FAPR + PALO + DEX. The superiority of HR20013 + DEX over FAPR + PALO + DEX in CR rate at the beyond delayed phase in cycle 1 was not met (90.3% v 86.5%; two-sided P = .11). In cycle 2, HR20013 + DEX showed greater proportions of patients reporting no impact on daily life at the delayed (24-120 hours) and beyond delayed phases compared with FAPR + PALO + DEX. The incidences of treatment-related adverse events were 35.7% during cycle 1 and 42.1% during entire study for HR20013 + DEX, versus 38.2% and 44.0% for FAPR + PALO + DEX. CONCLUSION HR20013 + DEX was noninferior to FAPR + PALO + DEX for preventing HEC-CINV and well tolerated, with the potential to reduce the impact of CINV on daily life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsAntineoplastic AgentsCisplatinNauseaPalonosetronVomitingAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDrug CombinationsIsoquinolinesMorpholinesNeoplasmsQuinuclidines

Substanzen

AntiemeticsAntineoplastic AgentsCisplatinDexamethasoneDrug CombinationsfosaprepitantIsoquinolinesMorpholinesPalonosetronQuinuclidines

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer…
  • Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
  • Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
  • Department of Oncology, Meihekou Central Hospital, Meihekou, China.
  • Department of Gynaecology, Linyi Cancer Hospital, Linyi, China.
  • Department of Pulmonary and Critical Care Medicine, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China.

ORCID-Profile: Jun Yao, Ruoyu Wang, Yan Yu, Wenfeng Fang, Yaxiong Zhang, Li Zhang

Zitieren

APA

Zhou, H., Zhao, Y., Zhang, M., Yao, J., Leng, S., Li, X., Lin, L., Chen, J., Zhang, S., Qin, X., Qin, Z., Yi, T., Wang, R., Li, X., Yu, Y., Wang, Z., Zheng, Q., Mei, J., Zang, A., …, & Zhang, L. (2025). Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01308

Vancouver

Zhou H, Zhao Y, Zhang M, Yao J, Leng S, Li X, et al. Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01308

BibTeX
@article{Zhou2025,
  author = {Zhou, Huaqiang and Zhao, Yuanyuan and Zhang, Mingjun and Yao, Jun and Leng, Shuang and Li, Xiumin and Lin, Li and Chen, Jinping and Zhang, Songnan and Qin, Xia and Qin, Zhiquan and Yi, Tienan and Wang, Ruoyu and Li, Xiang and Yu, Yan and Wang, Zhenghua and Zheng, Qinhong and Mei, Jiazhuan and Zang, Aimin and Li, Na and Cao, Fengjun and Cao, Ke and Li, Weiwei and Lu, Yanda and Lin, Dang and Zhou, Yan and Yang, Runxiang and Fang, Wenfeng and Zhou, Ningning and Yang, Yunpeng and Zhang, Yaxiong and Chen, Gang and Zhou, Ting and Yang, Xue and Wang, Huan and Wang, Yujiao and Huang, Yan and Zhang, Li},
  title = {Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-01308}
}
Kostenlos starten →